KD Logo

Aerovate Therapeutics Inc (AVTE) receives an Equal weight rating from Wells Fargo

Aerovate Therapeutics Inc’s filing revealed that its Director RA CAPITAL MANAGEMENT, L.P. acquired Company’s shares for reported $1.55 million on Jun 17 ’24. In the deal valued at $1.67 per share,928,110 shares were bought. As a result of this transaction, RA CAPITAL MANAGEMENT, L.P. now holds 7,893,678 shares worth roughly $13.42 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Then, Eldridge George A sold 15,000 shares, generating $375,450 in total proceeds. Upon selling the shares at $25.03, the insider now owns 5,022 shares.

Before that, Verwijs Marinus sold 10,600 shares. Aerovate Therapeutics Inc shares valued at $265,000 were divested by the CHIEF TECHNICAL OFFICER at a price of $25.00 per share. As a result of the transaction, Verwijs Marinus now holds 0 shares, worth roughly $0.0.

Wells Fargo downgraded its Aerovate Therapeutics Inc [AVTE] rating to an Equal weight from a an Overweight in a research note published on June 18, 2024; the price target was decreased to $2 from $35. A number of analysts have revised their coverage, including TD Cowen’s analysts, who decreased its forecast for the stock in mid June from “a Buy” to “a Hold”. Evercore ISI also remained covering AVTE and has decreased its forecast on June 18, 2024 with a “an In-line” recommendation from previously “an Outperform” rating. Wedbush revised its rating on June 17, 2024. It rated AVTE as “a Neutral” which previously was an “an Outperform”.

Price Performance Review of AVTE

On Monday, Aerovate Therapeutics Inc [NASDAQ:AVTE] saw its stock jump 2.41% to $1.70. Over the last five days, the stock has gained 13.33%. Aerovate Therapeutics Inc shares have fallen nearly -92.49% since the year began. Nevertheless, the stocks have fallen -89.36% over the past one year. While a 52-week high of $32.42 was reached on 04/01/24, a 52-week low of $1.25 was recorded on 06/20/24. SMA at 50 days reached $16.5050, while 200 days put it at $18.0225. A total of 1.27 million shares were traded, compared to the trading of 2.55 million shares in the previous session.

Levels Of Support And Resistance For AVTE Stock

The 24-hour chart illustrates a support level at 1.6233, which if violated will result in even more drops to 1.5467. On the upside, there is a resistance level at 1.7733. A further resistance level may holdings at 1.8467. The Relative Strength Index (RSI) on the 14-day chart is 23.17, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -6.1783, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 98.13%. Stochastics%K at 1.78% indicates the stock is a buying.

Most Popular